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pathological tumour stage (HR = 3.77; p = 0.020) and lymph 
node stage (HR = 2.34; p = 0.022) were significantly corre-
lated with CSS.  Conclusion: While the outcome of secondary 
MIBC is not generally adverse compared to primary MIBC, 
the EORTC risk score not only reflects high risk of progression 
of NMIBC to MIBC, but also worse outcome following RC for 
secondary MIBC. Timely RC should thus be debated in high-
risk NMIBC. 
 
Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Bladder cancer is the fourth most common cancer 
in men with severe impact on general health; it is gen-
erally divided into non-muscle-invasive bladder cancer 
(NMIBC) and muscle-invasive bladder cancer (MIBC) 
 [1] . Current guidelines recommend radical cystectomy 
(RC) with bilateral pelvic lymphadenectomy in MIBC 
and in NMIBC with high risk of progression  [2, 3] . Risk 
of progression to MIBC is usually determined by the 
EORTC risk score combining various clinicopathological 
parameters  [2–4] . Risk of cancer-specific mortality fol-
lowing RC for MIBC is usually determined by pathologi-
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 Abstract 
 Background: High-risk non-muscle-invasive bladder cancer 
(NMIBC) progressing to muscle-invasive bladder cancer 
(MIBC) is associated with adverse tumour biology. It is un-
clear, however, whether outcome of NMIBC progressing to 
MIBC is adverse compared to primary MIBC and whether 
NMIBC of higher risk of progression to MIBC is adverse com-
pared to NMIBC of lower risk.  Objective: Our objective was 
to assess cancer-specific survival (CSS) following radical cys-
tectomy (RC) for primary MIBC and for NMIBC progressing to 
MIBC in dependence of EORTC risk score.  Materials and 
Methods: Clinical and histopathological characteristics and 
CSS of 150 patients were assessed. Secondary MIBCs were 
stratified by EORTC risk score at the last transurethral resec-
tion of bladder tumour for NMIBC.  Results: CSS did not differ 
significantly between primary and secondary MIBC (p = 
0.521). Secondary MIBC with high EORTC score had signifi-
cantly shorter CSS compared to secondary MIBC with inter-
mediate EORTC score (p = 0.029). In multivariable analysis, 
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cal tumour stage and lymph node status. Since cancer-
specific survival (CSS) rates vary widely, other prognostic 
factors have been evaluated  [5, 6] .
 Progression of NMIBC to secondary MIBC, i.e. subse-
quent to preceding NMIBC as opposed to primary MIBC, 
could be a potential prognosticator conveying favourable 
outcome due to the initial non-muscle-invasive character 
of the bladder cancer or likewise a potential prognostica-
tor conveying adverse outcome due to its progressive tu-
mour biology.
 The EORTC risk score predicting progression of 
NMIBC to MIBC could also be a potential prognosticator 
conveying adverse outcome by again reflecting progres-
sive tumour biology. Should this scenario be true, debate 
of timely RC should be emphasized in the management 
of high-risk NMIBC and such debate should be based on 
EORTC risk scores. No conclusive data are available to 
date.
 Currently, indications for RC for bladder cancer stag-
es <pT2 are an issue of debate. While long-term bladder 
preservation is pursued for quality of life reasons, a ten-
dency to advocate RC in case of BCG-refractory and ini-
tially recurrent T1 tumour stage is notable in the recent 
literature, since favourable long-term outcome has been 
suggested for timely radical treatment  [7–11] . Due to 
prognostic uncertainty however the clinical management 
of high-risk NMIBC is demanding and any further prog-
nosticator valuable. We presently analyse CSS in a cur-
rent series of RC for primary compared to secondary 
MIBC to assess prognostic differences and analyse CSS in 
relation to EORTC risk score at the last transurethral re-
section of bladder tumour (TURBT) for NMIBC. No such 
data have been reported to date.
 Materials and Methods 
 Patient Selection 
 Clinical and histopathological data of consecutive patients un-
dergoing RC for clinically localized MIBC between 2004 and 2010 
at one tertiary urological centre without neoadjuvant chemother-
apy were collected.  Figure 1 shows the stratification of the patients 
into different risk groups. Patients were subdivided into two 
groups: patients with primary MIBC (group 1) and patients with 
secondary MIBC (group 2). In order to preserve homogenous pa-
tient groups we excluded patients with secondary MIBC, if no in-
travesical BCG therapy had been performed (n = 11) or no re-re-
section at the time of T1 stage and/or CIS had been performed 
(n = 3). In secondary MIBC, EORTC risk scores at the time of the 
last TURBT for NMIBC were assessed, resulting in a score from 0 
to 23  [4] : (a) number of tumours (single: 0, multiple: 3); (b) tumour 
size (<3 cm: 0,  ≥ 3 cm: 3); (c) prior recurrence rate (primary: 0, re-
current: 2); (d) T category (cTa: 0, cT1: 4); (e) presence of con-
comitant CIS (no: 0, yes: 6); (f) grade (G1–2: 0, G3: 5). Subsequent-
ly, we devised different risk groups, as reported by Sylvester et al. 
 [3] . Due to the frequent occurrence of high-risk patients we sub-
divided the high-risk group: (a) low-risk group: score <2; (b) inter-
mediate-risk group: score 2–6; (c) high-risk group A: score 7–13; 
(d) high-risk group B: score 14–23. Time from diagnosis of MIBC 
to RC and from initial TURBT for NMIBC to RC was dichot-
omised at 90 days in accordance with previous reports  [12–14] .
 Pathological Evaluation 
 Surgical specimens were processed according to standard insti-
tutional protocols. Tumour grading and staging was performed by 
genitourinary pathologists according to the 1973 World Health 
Organization (WHO) grading system and the American Joint 
Committee on Cancer (AJCC)-Union Internationale Contre le 
Cancer tumour, nodes, metastasis (TNM) classification, respec-
tively  [15, 16] .
 Follow-Up Regimen 
 Patients were followed according to institutional guidelines ef-
fective at that time largely reflecting current guidelines  [2] . For the 
first and from the second through the fifth year after RC, follow-up 
visits were scheduled every 3 and 6 months, respectively, and an-
nually thereafter with routine laboratory, ultrasound, urinary cy-
tology, chest radiography, radiographic evaluation of the upper 
urinary tract and cystoscopic evaluation of the neobladder. Bone 
scan, computed tomography and/or magnetic resonance imagings 
were performed when clinically indicated. Cause of death was de-
termined by the treating physician and death certificates.
 Statistical Analysis 
 The hypothesis of normality for all continuous variables was 
tested by the Shapiro-Wilk normality test. Means and standard 
deviations were displayed for the continuous stable distributed 
variables. Medians with interquartile ranges (IQRs) were used to 
Low-risk
<2
EORTC risk stratification
Intermediate-
risk
2–6
High-risk
7–23
High-risk A High-risk B
7–13 14–23
Patients with
MIBC
Group 1
Primary
MIBC
Secondary
MIBC
Group 2
 Fig. 1. Risk stratification of the patients according to EORTC. 
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present continuous not regularly distributed variables. Student’s t 
test was applied for variables with regular and Wilcoxon rank sum 
(Mann-Whitney) for variables with irregular distribution, respec-
tively. Categorical variables were compared by the χ 2 test. CSS was 
assessed by the Kaplan-Meier method from date of RC and impact 
of variables analysed by log-rank test. Impact of variables on CSS 
was assessed by uni- and multivariable Cox proportional Hazards 
regression models with backward stepwise elimination of criteria 
lacking significance. Subjects whose cause of death was not due to 
MIBC were censored at the time of death for CSS calculation. The 
statistical significance level was set at p < 0.05. All reported p values 
were two-sided. Statistical analysis was performed using SPSS ® 
v19.0 (SPSS Inc., Chicago, Ill., USA).
 Results 
 Clinical and Histopathological Outcome 
 Out of 150 patients, 125 (83.3%) underwent RC for 
primary MIBC and 25 patients (16.6%) for secondary 
MIBC. Clinical and histopathological characteristics are 
given in  table 1 . Mean age did not differ between primary 
and secondary MIBC (69; IQR 63–75.2 vs. 71; IQR 66.5–
77.5; p = 0.208). Male patients were predominant in both 
populations (77.6 vs. 96%; p = 0.048). In secondary MIBC 
the median number of TURBT was 3 (IQR 2–4.5) and the 
median time from initial TURBT to RC was 539 days 
(IQR 271.5–1,992.5). No differences in the rates of de-
layed RC (>90 days after diagnosis of muscle invasion;
p = 0.371), locally advanced tumour stages (pT3/4; p = 
0.652), concomitant CIS (p = 0.667), lymph node metas-
tasis (p = 0.824), lymphovascular invasion (p = 0.662), 
median number of lymph nodes removed (p = 0.753) and 
patients undergoing adjuvant chemotherapy (p = 1.000) 
were noted between primary and secondary MIBC. In 
secondary MIBC EORTC risk score of progression at the 
last TURBT for NMIBC was intermediate-risk in 6, high-
risk A in 9 and high-risk B in 10 patients.
 Oncological Outcome 
 The median follow-up was 46 months (IQR 31–62). In 
the entire population, CSS after 1, 3 and 5 years were 83, 
67 and 59%, respectively. Pathological tumour stage 
pT3/4 (HR = 3.77; p = 0.020) and lymph node metastasis 
(HR = 2.34; p = 0.022) were independently associated 
with CSS in multivariate analysis ( table 2 ). CSS did not 
differ significantly between primary and secondary MIBC 
(p = 0.521;  fig. 2 ). Patients with secondary MIBC classi-
fied as high-risk A of progression at the last TURBT for 
NMIBC (14–23) showed significantly worse CSS com-
pared to intermediate-risk or high-risk B patients (p = 
0.029 and p = 0.033;  fig. 3 ).
Table 1. Clinical and histopathological characteristics of primary and secondary MIBC
Criteria Entire cohort
(n = 150)
Primary MIBC
(n = 125)
Secondary MIBC
(n = 25)
p value
Median age (IQR), years 70 (64–76) 69 (63–75.2) 71 (66.5–77.5) 0.208
Male gender 121 (80.7%) 97 (77.6%) 24 (96.0%) 0.048
cT stage, first TURBT
<cT1
cT1
cT2
cT3/4
11 (7.3%)
12 (8.0%)
123 (82.0%)
4 (2.7%)
0
0
121 (96.8%)
4 (3.2%)
11 (44.0%)
14 (56.0%)
0
0
<0.001
Number of TURBT, median (IQR) 1 (1–1) 1 (1–1) 3 (2–4.5) <0.001
Median interval between first TURBT and RC, days (IQR) 40 (25–82) 33.5 (23.7–47.5) 539 (271.5–1,992.5) <0.001
Interval between TURBT due to MIBC and RC ≤90 days 140 (93.3%) 118 (94.4%) 22 (88.0%) 0.371
pT stage, RC
<pT3
pT3/4
57 (38.0%)
93 (62.0%)
49 (39.2%)
76 (60.8%)
8 (32.0%)
17 (68.0%)
0.652
pN+ stage, RC 59 (39.3%) 50 (40.0%) 9 (36.0%) 0.824
Grade 3, RC 139 (92.7%) 114 (91.2%) 25 (100%) 0.212
Concomitant CIS, RC 72 (48.3%) 61 (49.2%) 11 (44.0%) 0.667
Lymphovascular invasion, RC 85 (56.7%) 72 (57.6%) 13 (52.0%) 0.662
Median number of lymph nodes removed (IQR) 18 (14–23) 18 (13–23) 18 (14–23.5) 0.753
Adjuvant chemotherapy 35 (23.6%) 29 (23.4%) 6 (25.0%) 1.000
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 Discussion 
 Does Outcome of Primary and Secondary MIBC Differ? 
 No definitely conclusive data on survival rates after RC 
for secondary MIBC subsequent to preceding NMIBC 
compared to primary MIBC have been reported to date 
and the present literature is arbitrary. In 2002, Yiou et al. 
 [17] compared 43 and 12 patients with primary and sec-
ondary MIBC, respectively, reporting no difference in 
survival. May et al.  [18] compared 132 and 57 patients 
with primary and secondary MIBC, respectively, again 
finding no difference in outcome or any other clinico-
pathological parameter. While May at al.’s series was larg-
er than the present one, it was assessed in retrospect from 
various institutions while the present series was assessed 
prospectively with homogeneous treatment pattern due 
to institutional guidelines of one centre. In analogy to the 
present analyses, those series found no differences in out-
come between primary versus secondary MIBC  [17, 18] . 
A more recent retrospective series by de Vries et al.  [19] 
assessing 134 and 54 patients with primary and secondary 
MIBC, respectively, found comparable survival rates. The 
most recent series by Kotb et al.  [20] analysed 1,150 pa-
tients from the Canadian Bladder Cancer Network con-
taining 32% of patients with secondary MIBC. In this se-
ries, outcome of secondary MIBC was advantageous, as 
CSS at 5 years was 70% compared to 60% of primary 
MIBC. While age at MIBC was comparable, many other 
factors were adverse in primary MIBC, e.g. presence of 
preoperative hydronephrosis (20.8 vs. 32.6%; p = 0.0007), 
rate of higher pathological stage (T3/T4; 36.3 vs. 58.0%;
p = 0.0001), positive lymph nodes (20.1 vs. 28.8%; p = 
0.002) and rates of adjuvant chemotherapy (15.5 vs. 
23.3%; p = 0.002). The authors concluded that secondary 
MIBC may have better clinical and pathological outcome. 
In contrast to the present series no details on NMIBC 
prior to MIBC were available and according to the au-
thors different approaches toward early cystectomy in 
each centre might have biased the results  [20] .
 In accordance with the former series and in contrast to 
the most recent analysis our data again do not suggest gen-
erally adverse outcome of either variation. No other factor 
biasing CSS was noted in the present series. The ratio of 
patients with secondary MIBC of all patients undergoing 
RC for MIBC in the present series was 25% and thus with-
in the range of previous series (21.4 to 29.4%)  [18–22] . No 
differences in e.g. tumours stage, lymph node status or use 
of adjuvant chemotherapy were noted. Thus the present 
homogeneous and well-controlled data, also including de-
tailed information of NMIBC preceding MIBC, suggest 
comparable outcome for primary and secondary MIBC.
 Does Risk of Progression of NMIBC Matter for 
Outcome of Secondary MIBC? 
 Risk of progression does convey adverse tumour biol-
ogy; accordingly the outcome of RC for high-risk NMIBC 
is still compromised in some cases despite radical tumour 
removal. Accordingly, risk of progression at time of last 
TURBT for NMIBC prior to MIBC could reflect outcome. 
To date, only one series assessed risk of progression; de 
Vries et al.  [19] stratified 54 NMIBC in one low/intermedi-
ate- and one high-risk group (n = 25 and n = 29, respec-
Table 2.  Uni- and multivariable Cox regression analysis of CSS
Criteria Univariable analysis,
HR (95% CI)
p value Multivariable analysis,
HR (95% CI), backward 
stepwise elimination
p value
Age, cont. 1.03 (0.99–1.06) 0.128 n.s.
Female gender (referent male) 1.42 (0.68–2.94) 0.351 n.s.
Interval between first TURBT and RC, cont. 1.00 (1.00–1.00) 0.984 n.s.
Interval between TURBT due MIBC and RC >90 days 
(referent ≤90 days)
1.26 (0.45–3.52) 0.657 n.s.
pT3/4 stage, RC (referent ≤pT2) 8.95 (3.19–25.05) <0.001 3.77 (1.24–11.47) 0.020
pN+ stage, RC (referent pN0) 5.05 (2.68–9.51) <0.001 2.34 (1.13–4.84) 0.022
Grade 3, RC (referent <grade 3) 3.94 (0.54–28.56) 0.175 n.s.
Concomitant CIS, RC (referent absent CIS) 0.95 (0.53–1.70) 0.858 n.s.
Lymphovascular invasion, RC (referent absent LVI) 5.66 (2.53–12.68) <0.001 n.s.
Number of lymph nodes removed, cont. 1.00 (0.97–1.03) 0.988 n.s.
Adjuvant chemotherapy (referent no adjuvant chemotherapy) 3.71 (2.03–6.75) <0.001 n.s.
Secondary muscle invasion (referent primary) 0.77 (0.34–1.72) 0.524 n.s.
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tively), reporting 5-year survival rates of 75 vs. 35%, respec-
tively. While numbers are comparably small in de Vries et 
al.’s and our series, we found comparable CSS rates for pa-
tients with high EORTC risk scores (67% for the high-risk 
A group) and markedly advantageous outcome in patients 
with low EORTC risk scores of progression (p = 0.029).
 Which Conclusions Can Be Drawn for the 
Management of High-Risk NMIBC? 
 Outcome of secondary MIBC is generally critical; 
some 50% of the patients with cT2N0M0 had died from 
disease after 5 years. While this can be partly attributed to 
the high rate of upstaging to tumour stages  ≥ pT3 and/or 
pN+, which is in accordance with the recent series by de 
Vries et al. and has been reported for up to 50% of all pa-
tients undergoing RC for MIBC  [19, 22] , it stresses the 
need for close follow-up of NMIBC at risk of progression. 
The present data furthermore demonstrate secondary 
MIBC subsequent to preceding NMIBC at high risk of 
progression to be brittle. Accordingly, debate of early RC 
should be considered previous to MIBC in high-risk 
NMIBC. This aspect is all the more challenging in the ab-
sence of reliable prognosticators of high-risk NMIBC. Re-
cently, shortcomings of current grading systems for prog-
nostic assessment were suggested  [23] . Likewise, substag-
ing of pT1 NMIBC in relation to depth of lamina propria 
invasion has been proposed due to inaccuracy of prog-
nostic assessment  [24, 25] . Molecular markers seem not 
to suffice in this regard and require further assessment  [5, 
26, 27] . Thus, the present data emphasize the use of the 
EORTC risk score of progression in high-risk NMIBC to 
gain some additional prognostic information.
 Which Limitations of the Present Series Need to Be 
Taken into Account? 
 The present series is marked by several limitations. For 
one, the present dataset is small, containing but 25 pa-
tients with secondary MIBC. To date, no considerably 
larger dataset which is fairly homogeneous and well-con-
trolled for biasing factors has been reported. Second, while 
the present data were assessed prospectively, EORTC risk 
scores were assigned retrospectively for the earlier years of 
the present series based on clinicopathological character-
istics assessed at the time of TURBT. Third, while control 
for use of BCG therapy had been exerted in secondary 
MIBC, no exact control for number of doses and duration 
of therapy could be achieved. Fourth, no patient in the 
present series obtained neoadjuvant chemotherapy de-
spite more recent respective recommendations  [3] , which 
could compromise comparability to other data.
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 Fig. 2. Probability estimates of CSS in primary MIBC (n = 125; 
prim-MIBC) and secondary MIBC (n = 25; sec-MIBC). 
 Fig. 3. Probability estimates of CSS after RC in primary MIBC
(n = 125; prim-MIBC) and secondary MIBC stratified according 
to the EORTC risk scores of progression predicting at time of last 
TURBT for NMIBC [intermediate-risk group (score 2–6) n = 6 vs. 
high-risk A group (score 7–13) n = 9 vs. high-risk B group (score 
14–23) n = 10]. 
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 Conclusions 
 Outcome of secondary MIBC subsequent to previous 
NMIBC is not generally adverse compared to primary 
MIBC. In high-risk NMIBC debate of early RC should be 
considered, since high EORTC risk scores of progression 
at the last TURBT for NMIBC convey poor prognosis not 
only for progression to MIBC but also for outcome of sec-
ondary MIBC following RC.
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